Navigation Links
New study on popular prostate cancer protein provides insight into disease progression
Date:6/25/2013

LOS ANGELES (June 25, 2013) Researchers at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute have uncovered for the first time the vital role a popular protein plays in the stroma, the cell-lined area outside of a prostate tumor.

Researchers have long understood the function of the protein, Caveolin-1 (Cav-1), in prostate cancer, including its role in treatment resistance and disease aggressiveness. However, prior to this study, little was known about the role of Cav-1 within the stroma.

The study, published in the Journal of Pathology, found that a decreased level of the Cav-1 protein in the stroma indicated tumor progression a function opposite to the known role of Cav-1 within a tumor. Inside the tumor, an increased level of this protein signifies tumor progression. These human tumor findings suggest that patients whose prostate tumor is surrounded by a stroma with decreased levels of the Cav-1 protein may have an overall worse prognosis and a higher chance of disease relapse.

"How a prostate tumor communicates with its microenvironment, or stroma, is a vital process we need to understand to assess the aggressiveness of a patient's disease and potential response to treatment," said Dolores Di Vizio, MD, PhD, associate professor in the Urologic Oncology Research Program and senior investigator of the study. "This research suggests that the cells surrounding a prostate tumor are equally as important as the tumor itself in helping understand the complexity of a man's disease. This early-stage research may provide a new, future marker that may ultimately aid diagnosis and treatment, and personalize prostate cancer therapy."

In addition to understanding the role of Cav-1 in the tumor microenvironment, researchers discovered that the loss of Cav-1 causes an increase of cholesterol in the stroma. Previous research findings suggest that cholesterol levels are related to aggressive prostate cancer, but cholesterol's role had never been evaluated within the stroma.

"Cholesterol has been shown to be a driver of prostate cancer progression," said Di Vizio. "For the first time in prostate cancer research, we found that when levels of Cav-1 decrease in the stroma, both cholesterol and androgens increase. This finding may partly explain a resistance to traditional treatments."

Though the findings are preliminary, the Cedars-Sinai researchers Di Vizio, Michael Freeman, PhD, vice chair of research in the Department of Surgery and professor/director of the Cancer Biology Program at the Samuel Oschin Comprehensive Cancer Institute, and post-doctoral fellows Matteo Morello, PhD, and Sungyong You, PhD, will continue evaluating the role of the Caveolin-1 protein in the stroma and its potential end benefit in patients.


'/>"/>

Contact: Cara Lasala
cara.lasala@cshs.org
310-423-7798
Cedars-Sinai Medical Center
Source:Eurekalert

Related medicine news :

1. Study finds dramatic increase in hospitalization of US children with inflammatory bowel disease
2. GAP-AF study helps to define optimal approach to ablation
3. New Study: Alcohol Drinkers May Face Long Term Health Issues
4. A Study Shows That Mom’s Obesity Surgery May Help Break Cycle in Obese Kids
5. New Study Casts Doubt on FDA Pradaxa Conclusions
6. Results of landmark 11-year study on weight losss effect on heart disease risks published today
7. Rottenstein Law Group LLP Acknowledges BMJ Study of Risks of Byetta, Januvia
8. JAAOS Study Exposes Importance of Child Safety Seats for Children between Four and Eight – Kiley Law Group, LLC
9. Renowned Hudson Valley ENT Sleep Specialist Selected to Participate in FDA Study of New Obstructive Sleep Apnea Treatment
10. SMU researcher receives Hogg Foundation grant to study childhood depression
11. Depression screening in AF Clinics recommended by study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... Wells Pharmacy ... attending prescribers at the upcoming World Congress, in Hollywood Florida April 6-8, 2017. ... recognized as the visionary leader in the training of physicians, scientists, and members ...
(Date:3/29/2017)... BC (PRWEB) , ... March 29, 2017 , ... ... makeover services with or without a referral to new patients from Burnaby, BC. ... or other full mouth reconstruction services, can see the esteemed team at ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... FASTBRACES® in Carnegie, OK, from Dr. Jamie Cameron, with or without ... efficiently, compared to traditional orthodontic treatment. Depending on each patient’s case, treatment with ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... as it continues developing an ANSI-approved, consensus-based American National Standard for Good ... to publish the first ANSI-approved GMP standard for dietary supplements this spring, ...
(Date:3/29/2017)... ... March 29, 2017 , ... Altima Technologies, Inc., ... network and data center assets and audio-video devices has recently updated its Visio ... shapes for free and download shapes and stencils from http://www.VisioStencils.com. , ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... YORK , March 29, 2017 Global intravenous ... US$ 3 billion by 2021, growing at a CAGR of ... iron prescribed by a doctor to treat anemia or other ... iron level in the body. However, in some cases, oral ... the body and intravenous (IV) iron therapy comes into the ...
(Date:3/29/2017)... March 29, 2017  BioSpecifics Technologies Corp. (NASDAQ: ... to develop collagenase based-therapies with a first in ... as XIAFLEX ®  in the U.S. and Xiapex ... a corporate overview at the upcoming 16 th ... 5, 2017 at 8:00 a.m. ET in ...
(Date:3/29/2017)... 29, 2017 Research and Markets has announced the ... Therapy Centers & Forecast" report to their offering. ... Proton Therapy Market in Italy ... value in 2016. There are currently three proton therapy centers in ... more patients. In Italy , the first patients were ...
Breaking Medicine Technology: